In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Armata Pharmaceuticals (ARMP – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $1.75.
Pantginis covers the Healthcare sector, focusing on stocks such as Clene, Palatin Technologies, and Checkpoint Therapeutics. According to TipRanks, Pantginis has an average return of -14.1% and a 32.02% success rate on recommended stocks.
Currently, the analyst consensus on Armata Pharmaceuticals is a Moderate Buy with an average price target of $8.00, which is a 357.14% upside from current levels. In a report released on March 7, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $9.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $5.79 and a one-year low of $0.83. Currently, Armata Pharmaceuticals has an average volume of 22.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
Read More on ARMP:
